EGF816 + trametinib + ribociclib + LXH254 + INC280 + gefitinib
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR-mutant Non-small Cell Lung Cancer
Conditions
EGFR-mutant Non-small Cell Lung Cancer
Trial Timeline
Jan 29, 2018 → Oct 5, 2026
NCT ID
NCT03333343About EGF816 + trametinib + ribociclib + LXH254 + INC280 + gefitinib
EGF816 + trametinib + ribociclib + LXH254 + INC280 + gefitinib is a phase 1 stage product being developed by Novartis for EGFR-mutant Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03333343. Target conditions include EGFR-mutant Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03333343 | Phase 1 | Active |
Competing Products
2 competing products in EGFR-mutant Non-small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| erlotinib | Astellas Pharma | Phase 1 | 33 |
| famitinib po + HS-10296 po | Jiangsu Hengrui Medicine | Phase 2 | 52 |